Correction to Lancet Oncol 2024; 25: 1325–36

Abstract

Iliopoulos O, Iversen AB, Narayan V, et al. Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 study. Lancet Oncol 2024; 25: 1325–36—In this Article, the second sentence in the fifth paragraph of the Results section, should read “After initiating belzutifan treatment, one patient (2%) underwent two CNS-related surgeries (cyst drainage and haemangioblastoma removal for the same lesion), and one patient (2%) received local radiotherapy approximately 5 weeks after starting belzutifan treatment.” These corrections have been made to the online version as of Oct 28, 2024.